FAAH

Fatty acid amide hydrolase

FAAH (Fatty acid amide hydrolase) is a membrane-bound protein belonging to serine hydrolase family of enzymes.FAAH is responsible for the hydrolysis of a number of important endogenous fatty acid amides, including the endogenous cannabimimetic agent anandamide (AEA), the sleep-inducing compound oleamide, and the putative anti-inflammatory agent palmitoylethanolamide (PEA). FAAH plays a significant role in termination of signalling of a class of bioactive lipids called fatty acid amides (FAAs) both in the central nervous system (CNS) and peripheral tissues.

FAAH belongs to the amidase signature (AS) superfamily and is widely distributed in multicellular eukaryotes. FAAH has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol.

FAAH Inhibitors

1-Monomyristin

Cat. No.: HY-N2512

1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC_{50}=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC_{50}=18 μM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

AA38-3

Cat. No.: HY-18544

AA38-3 is a **serine hydrolase (SH)** inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Acetylhydrolase-IN-1

Cat. No.: HY-102054

Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (**Alkylacetyl-GPC: acetylhydrolase**) inhibtor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIA 10-2474

Cat. No.: HY-19740

BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (**FAAH**) with IC_{50} values of 50 to 70mg/kg in various rat brain regions.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BIA 10-2474-d3

Cat. No.: HY-19740S

BIA 10-2474-d3 is the deuterium labeled BIA 10-2474. BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (**FAAH**) with IC_{50} values of 50 to 70mg/kg in various rat brain regions.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Biochanin A

(4-Methylgenistein; Olmelin)

Cat. No.: HY-14595

Biochanin A is a naturally occurring fatty acid amide hydrolase (**FAAH**) inhibitor, which inhibits FAAH with IC_{50}s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 500 mg

Carprofen

Cat. No.: HY-B1227

Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with IC_{50}s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Carprofen-d3

Cat. No.: HY-B1227S

Carprofen-d3 is the deuterium labeled Carprofen. Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with IC_{50}s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Dual FAAH/sEH-IN-1

Cat. No.: HY-144738

Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual **sEH** (soluble epoxide hydrolase) and **FAAH** (fatty acid amide hydrolase) inhibitor, with IC_{50} values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH inhibitor 1

(Benzothiazole analog 3)

Cat. No.: HY-10862

FAAH inhibitor 1 (Benzothiazole analog 3) is a potent **fatty acid amide hydrolase (FAAH)** inhibitor with an IC_{50} of 18±8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

FAAH-IN-1

Cat. No.: HY-111389

FAAH-IN-1 is a fatty acid amide hydrolase (**FAAH**) inhibitor, with IC_{50}s of 145 nM and 650 nM for rat and human FAAH, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH-IN-2

(O-Desmorpholinopropyl Gefitinib)

Cat. No.: HY-79511

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

FAAH-IN-5

Cat. No.: HY-146341

FAAH-IN-5 (Compound 7) is a relative selective, irreversible **fatty acid amide hydrolase (FAAH)** inhibitor with an IC_{50} of 10.5 nM. FAAH-IN-5 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH/MAGL-IN-1

Cat. No.: HY-143263

FAAH/MAGL-IN-1 (compound SIH 3) is a potent **FAAH** and **MAGL** inhibitor with IC_{50}s of 31 nM and 29 nM, respectively. FAAH/MAGL-IN-1 has the potential for the research of neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH/MAGL-IN-2

Cat. No.: HY-143264

FAAH/MAGL-IN-2 is a potent, reversible, orally active, and cross the blood-brain barrier **FAAH** and **MAGL** inhibitor with IC_{50}s of 11 nM and 36 nM (K_is of 28 nM and 60 nM), respectively .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH/MAGL-IN-3

Cat. No.: HY-146342

FAAH/MAGL-IN-3 (Compound 10) is an irreversible **fatty acid amide hydrolase (FAAH)** and monoacylglycerol lipase (MAGL) dual inhibitor with IC_{50} values of 179 and 759 nM against FAAH and MAGL, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-1661010

(Takeda-25)

Cat. No.: HY-N7062

JNJ-1661010 (Takeda-25) a potent and selective **fatty acid amide hydrolase (FAAH)** inhibitor with IC_{50}s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics.



Purity: 98.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-42165279

Cat. No.: HY-19636

JNJ-42165279 is a FAAH inhibitor with IC50 of 70 ± 8 nM and 313 ± 28 nM for hFAAH and rFAAH, respectively.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

JZL195

Cat. No.: HY-15250

JZL195 is a selective and efficacious dual **fatty acid amide hydrolase (FAAH)** and **monoacylglycerol lipase (MAGL)** inhibitor with IC_{50}s of 2 and 4 nM, respectively.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY2183240

Cat. No.: HY-10865

LY2183240 is a highly potent blocker of **anandamide uptake** (IC_{50}= 270 pM; K_i=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase **(FAAH)** with an IC_{50} of 12.4 nM.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

MAGL-IN-5

Cat. No.: HY-119283

MAGL-IN-5 is a non-selective lipase inhibitor with IC_{50} values of 144, 90, and 14 nM for human recombinant **monoacylglycerol lipase(MAGL)**,**hormone sensitive lipase(HSL)**, and **fatty acid amide hydrolase(FAAH)** respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK-4409

Cat. No.: HY-12909

MK-4409 is a potent oxazole **FAAH** inhibitor and can be used for the research of inflammatory and neuropathic pain.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-(3-Methoxybenzyl)Palmitamide

Cat. No.: HY-N2428

N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of **FAAH** for the treatment of pain, inflammation and CNS degenerative disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

N-Benzyloleamide

Cat. No.: HY-N6923

N-Benzyloleamide is a maccamide isolated from Lepidium meyenii (Maca). N-Benzyloleamide irreversibly inhibits fatty acid amide hydrolase **(FAAH)**. N-benzyloleamide influences the energy metabolism and reveals antioxidant and antifatigue activities.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

N-Benzylpalmitamide

(N-Benzylhexadecanamide; Macamide 1)

Cat. No.: HY-N2365

N-Benzylpalmitamide is a macamide isolated from Lepidium meyenii, acts as an inhibitor of **fatty acid amide hydrolase (FAAH)**.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 1 mg

N-Benzyllinolenamide

Cat. No.: HY-N3033

N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (**FAAH**) with an IC_{50} of 41.8 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PF 750

Cat. No.: HY-18081

PF 750 is a selective and covalent **fatty acid amide hydrolase (FAAH)** inhibitor, with IC_{50}**s** varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme's active site serine nucleophile.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg

PF-04457845

Cat. No.: HY-14376

PF-04457845 is a highly efficacious and selective **FAAH** inhibitor with IC_{50} values is 7.2±0.63 nM and 7.4±0.62 nM for **hFAAH** and **rFAAH**, respectively.



Purity: 99.37%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-3845

Cat. No.: HY-14380

PF-3845 is a potent, selective, irreversible and orally active inhibitor of **fatty acid amide hydrolase (FAAH)**, with a K_i of 0.23 μM. PF-3845 is a covalent inhibitor that carbamylates FAAH's serine nucleophile.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SA 47

Cat. No.: HY-18080

SA 47 is a selective and potent inhibitor of **fatty acid amide hydrolase (FAAH)** and **carbamate**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SA57

Cat. No.: HY-103463

SA57 is a potent, selective **FAAH** inhibitor with **IC_{50}**s of 3.2 nM and 1.9 nM for **mouse and human FAAH**.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SA72

Cat. No.: HY-U00240

SA72 is a highly selective **fatty acid amide hydrolase (FAAH)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSR411298

Cat. No.: HY-123863

SSR411298 is an orally active, selective and reversible **fatty acid amide hydrolase (FAAH)** inhibitor. SSR411298 has the potential for post-traumatic stress disorder research.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

URB-597

(KDS-4103)

Cat. No.: HY-10864

URB-597 (KDS-4103) is an orally bioavailable and selective **FAAH** inhibitor. URB-597 inhibits FAAH activity with an **IC_{50}**s of approximately 5 nM in rat brain membranes, 0.5 nM in intact rat neurons, 3 nM in human liver microsomes. Antidepressant-like effects. Analgesic activity.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

URB937

Cat. No.: HY-116477

URB937 is an orally active and peripherally restricted **FAAH** inhibitor (**IC_{50}**=26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier).



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg